Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution
Authors:
Open Access
- 1 March 2009
- journal article
- review article
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. 3, 199-210
Abstract
Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution Hyung Cho1, Kenneth J Wolf1, Eric J Wolf21Department of Ophthalmology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, USA; 2Department of Ophthalmology, Edward S. Harkness Eye Institute of Columbia University College of Physicians and Surgeons, New York, NY, USA Recently, several new ophthalmic NSAID products have been introduced for commercial use in the United States. The purpose of this review is to briefly overview the ophthalmic NSAIDs currently in use and to discuss the management of postoperative ocular inflammation and pain following cataract surgery with a particular focus on bromfenac ophthalmic solution 0.09%. Bromfenac ophthalmic solution 0.09% is indicated for the reduction of ocular pain and inflammation following cataract surgery. Studies have shown that bromfenac ophthalmic solution 0.09% has equivalent efficacy to the other topical NSAIDs in reducing postsurgical inflammation and controlling pain. The unique chemical structure of bromfenac makes it both a potent inhibitor of the COX-2 enzyme and a highly lipophilic molecule that rapidly penetrates to produce early and sustained drug levels in all ocular tissues. Clinically, these pharmacokinetic features are manifested in a rapid reduction of postsurgical inflammation and pain with bid dosing. Bromfenac ophthalmic solution 0.09% is a versatile agent and is effective when used as either monotherapy or as an adjunct therapy to steroids.Keywords: bromfenac, ophthalmic NSAIDs, ocular inflammationKeywords
This publication has 58 references indexed in Scilit:
- Topical Ocular Delivery of NSAIDsThe AAPS Journal, 2008
- The Systemic Safety of Bromfenac Ophthalmic Solution 0.09%Journal of Ocular Pharmacology and Therapeutics, 2007
- Nepafenac-associated corneal meltJournal of Cataract & Refractive Surgery, 2007
- Intravitreal steroids in the management of macular oedemaActa Ophthalmologica Scandinavica, 2006
- Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodiumCurrent Medical Research and Opinion, 2006
- Global Experience With Xibrom (Bromfenac Ophthalmic Solution) 0.09%: The First Twice-daily Ophthalmic Nonsteroidal Anti-inflammatory DrugInternational Ophthalmology Clinics, 2006
- Incidence of Cystoid Macular Edema after Uncomplicated PhacoemulsificationOphthalmologica, 2003
- Ketorolac in the Era of Cyclo-Oxygenase-2 Selective Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review of Efficacy, Side Effects, and Regulatory IssuesPain Medicine, 2001
- The Role of Nonsteroidal Antiinflammatory Drugs in Ocular InflammationInternational Ophthalmology Clinics, 1996
- Antiinflammatory agents. 3. Synthesis and pharmacological evaluation of 2-amino-3-benzoylphenylacetic acid and analogsJournal of Medicinal Chemistry, 1984